Compile Data Set for Download or QSAR
Report error Found 98 Enz. Inhib. hit(s) with all data for entry = 7539
LigandPNGBDBM200316(US9227956, 1)
Affinity DataIC50: 440nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200332(US9227956, 16)
Affinity DataIC50: 520nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200354(US9227956, 39 | US9227956, 38)
Affinity DataIC50: 592nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200325(US9227956, 10)
Affinity DataIC50: 640nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200317(US9227956, 2)
Affinity DataIC50: 690nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200328(US9227956, 13)
Affinity DataIC50: 800nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200332(US9227956, 16)
Affinity DataIC50: 800nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200318(US9227956, 3)
Affinity DataIC50: 800nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200325(US9227956, 10)
Affinity DataIC50: 1.50E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200320(US9227956, 5)
Affinity DataIC50: 1.50E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200321(US9227956, 6)
Affinity DataIC50: 1.50E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200327(US9227956, 12)
Affinity DataIC50: 1.70E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200321(US9227956, 6)
Affinity DataIC50: 1.70E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200317(US9227956, 2)
Affinity DataIC50: 1.70E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200324(US9227956, 9)
Affinity DataIC50: 1.80E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200326(US9227956, 11)
Affinity DataIC50: 2.10E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200354(US9227956, 39 | US9227956, 38)
Affinity DataIC50: 2.19E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200328(US9227956, 13)
Affinity DataIC50: 2.30E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200341(US9227956, 25)
Affinity DataIC50: 2.97E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200333(US9227956, 17)
Affinity DataIC50: 3.05E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200330(US9227956, 15a)
Affinity DataIC50: 3.10E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200316(US9227956, 1)
Affinity DataIC50: 3.20E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200366(US9227956, 51 | US9227956, 50)
Affinity DataIC50: 3.56E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200323(US9227956, 8)
Affinity DataIC50: 3.70E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200319(US9227956, 4)
Affinity DataIC50: 3.80E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200360(US9227956, 45 | US9227956, 44)
Affinity DataIC50: 4.39E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200329(US9227956, 14)
Affinity DataIC50: 4.50E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200362(US9227956, 47 | US9227956, 46)
Affinity DataIC50: 4.67E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200331(US9227956, 15b)
Affinity DataIC50: 5.00E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200350(US9227956, 35 | US9227956, 34)
Affinity DataIC50: 5.22E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200352(US9227956, 37 | US9227956, 36)
Affinity DataIC50: 5.43E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200334(US9227956, 18)
Affinity DataIC50: 5.61E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200342(US9227956, 26)
Affinity DataIC50: 5.75E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200338(US9227956, 22)
Affinity DataIC50: 5.80E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200350(US9227956, 35 | US9227956, 34)
Affinity DataIC50: 6.20E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200348(US9227956, 33 | US9227956, 32)
Affinity DataIC50: 7.26E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200330(US9227956, 15a)
Affinity DataIC50: 7.30E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200358(US9227956, 43 | US9227956, 42)
Affinity DataIC50: 7.38E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200364(US9227956, 49 | US9227956, 48)
Affinity DataIC50: 7.68E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200366(US9227956, 51 | US9227956, 50)
Affinity DataIC50: 8.03E+3nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200323(US9227956, 8)
Affinity DataIC50: 9.50E+3nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200368(US9227956, 53 | US9227956, 52)
Affinity DataIC50: 1.07E+4nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200331(US9227956, 15b)
Affinity DataIC50: 1.07E+4nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200326(US9227956, 11)
Affinity DataIC50: 1.17E+4nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200354(US9227956, 39 | US9227956, 38)
Affinity DataIC50: 1.18E+4nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200370(US9227956, 55 | US9227956, 54)
Affinity DataIC50: 1.28E+4nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200343(US9227956, 27)
Affinity DataIC50: 1.43E+4nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200364(US9227956, 49 | US9227956, 48)
Affinity DataIC50: 1.54E+4nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200356(US9227956, 41 | US9227956, 40)
Affinity DataIC50: 1.54E+4nMAssay Description:In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

LigandPNGBDBM200346(US9227956, 30)
Affinity DataIC50: 1.67E+4nMAssay Description:An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2016
Entry Details
US Patent

Displayed 1 to 50 (of 98 total ) | Next | Last >>
Jump to: